Credit Suisse analyst Matt Miksic initiated Wright Medical with an Outperform rating and a price target of $33 as part of his broader research note on Medical Supplies and Devices partially titled "No Disruption, No Alpha". The analyst says the company looks "well positioned to generate improving cash flows and EBITDA margins" after "managing substantial operating challenges in late 2017 and 2018". Miksic also cites Wright Medical's "market-leading shoulder business, highly differentiated and expanding regenerative biologics product line in Augment, realigned lower-extremity distribution network showing signs of reacceleration, and a best-in-class management team".